secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARVARD BIOSCIENCE INC (HBIO)
CIK:        0001123494
Form:       8-K
Filed at:   2023-04-25T23:59:59+00:00
Accession:  0001171843-23-002499
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harvard Bioscience Q1 revenue $30M (+4% YoY); net income $0.6M vs $6.9M loss; adj EBITDA margin 16%
--------------------------------------------------------------------------------

- Q1 revenues $30.0M, up 4% from $28.8M in Q1'22; gross margin improved to 61% from 56%.
- GAAP net income $0.6M ($0.01 diluted EPS) vs net loss of $6.9M ($0.17 loss) in Q1'22.
- Adjusted EBITDA $4.8M (16% margin) vs $2.7M (9% margin) in prior year.
- Paid down debt by $2.8M; net debt $41.0M; targeting net leverage ~2x by year-end.
- Full-year 2023 guidance: mid-single digit revenue growth, gross margins ~60%, adjusted EBITDA margins 16-17%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1123494/000117184323002499/0001171843-23-002499-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1123494/000117184323002499/f8k_042523.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-002499

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer